Filter by Category: Medical Writing

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide.

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide. by Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, Jr. and DiGiandomenico A published in J. Infect. Dis. 2016; 213 (4): 640-648

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. by Sanchez EH, Mendes RE, Sader HS and Allison GM published in J. Antimicrob. Chemother. 2016; 71 (6): 1736-1738

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014.

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014. by Sader HS, Castanheira M, Flamm RK, Huband MD and Jones RN published in Surg. Infect. (Larchmt). 2016; 17 (4): 473-478

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014.

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. by Pfaller MA, Flamm RK, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5393-5399

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model. by Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2075-2080

Comparison of BD Max StaphSR and BD Max MRSAXT for screening of Staphylococcus aureus clinical isolates collected from hospitals in the United States.

Comparison of BD Max StaphSR and BD Max MRSAXT for screening of Staphylococcus aureus clinical isolates collected from hospitals in the United States. by Mendes RE, Watters AA, Rhomberg PR, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2016; 54 (6): 1668-1669

Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226.

Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226. by Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE and Flamm RK published in Antimicrob. Agents Chemother. 2016; 60 (7): 4404-4406

Effect of the β-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae.

Effect of the β-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. by Castanheira M, Rhomberg PR, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5454-5458

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center.

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. by Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M and Chemaly RF published in Clin. Infect. Dis. 2016; 63 (7): 954-958

Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014.

Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014. by Sader HS, Flamm RK, Mendes RE, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2558-2563